BioCentury This Week

BioCentury Podcasts
  • 5,0 (25)
  • SCIENCE DE LA VIE
  • CHAQUE SEMAINE
BioCentury This Week

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

  1. Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals

    -4 J

    Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals

    Giving RFK Jr. control of HHS would be disastrous, argues Washington Editor Steve Usdin on the latest BioCentury This Week podcast. Expanding on his Editor’s Commentary, Usdin explains why Kennedy would be an unmitigated disaster for FDA, NIH and CMS, for biopharmas and for patients. He calls on biopharma leaders to speak out and affirm basic truths, even if it puts them in harm’s way.BioCentury’s editors also discuss why new data for GSK's Blenrep — an oncology therapy withdrawn two years ag...

    30 min
  2. Ep. 264 - Prepping for Trump & Alzheimer's Ethics

    12 NOV.

    Ep. 264 - Prepping for Trump & Alzheimer's Ethics

    Trump 2.0 presents opportunities and challenges for leaders of the biopharma industry, which needs effective public policy to thrive. On the latest BioCentury This Week, BioCentury Washington Editor Steve Usdin explains what those opportunities are and lays out the potential impact on the public policy environment, which could have repercussions on FDA and beyond.BioCentury’s editors then analyze how companies, academics and advocates are pushing back on claims that they should have disclosed...

    29 min
  3. Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser

    5 NOV.

    Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser

    It’s too soon to conclude anti-amyloid therapies are safe for use by Alzheimer’s patients in the real world, even as early reports are encouraging, argues BioCentury Executive Editor Selina Koch on the latest BioCentury This Week podcast. Koch and colleagues discuss takeaways from this year’s Clinical Trials on Alzheimer’s Disease annual meeting, including conclusions from adverse event data for Leqembi lecanemab and what the true test of appropriate use and safety for the drug might look lik...

    35 min
  4. Ep. 262 - EGFR Case Study, FDA & Politics

    29 OCT.

    Ep. 262 - EGFR Case Study, FDA & Politics

    Twenty years of innovation in therapies targeting EGFR provides a case study in how generation of differentiated products against the target can drive market growth. On the latest BioCentury This Week podcast, BioCentury’s editors discuss EGFR as a prime example of the value in best-in-class development strategies, with meaningful improvements across multiple modalities delivering substantial therapeutic benefits to patients. Analogous best-in-class opportunities aren’t limited to cancer, but...

    24 min
  5. Ep. 261 - China Summit: Reinventing Your China Strategy

    24 OCT.

    Ep. 261 - China Summit: Reinventing Your China Strategy

    Cross-border geopolitical tensions and a prolonged capital crunch are compelling biopharma companies from Beijing to Boston to rethink their strategies on everything from deal-making and raising capital to manufacturing and use of CROs. On a special edition of the BioCentury This Week podcast, McKinsey’s Franck Le Deu and Wendy Pan of BayHelix and Goodwin join BioCentury on the eve of next week’s eleventh annual BioCentury-BayHelix China Healthcare Summit in Shanghai to discuss the dynamics a...

    32 min
  6. Ep. 260 - VC Funds, New Chapter for MS, Wave's Data

    22 OCT.

    Ep. 260 - VC Funds, New Chapter for MS, Wave's Data

    At least 25 venture firms have raised a total of more than $17 billion in funds this year, with Forbion unveiling the largest-ever European biopharma fund at €1.2 billion last week. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how Forbion deployed its prior fund and quickly raised fresh funds and what that — and other funds — say about the state of financing private biotechs in Europe and elsewhere.The editors then assess takeaways from BioCentury’s conversation wi...

    31 min
  7. Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA

    15 OCT.

    Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA

    There is a growing mandate among researchers and VCs to provide proof of causal human biology for new targets. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the different strategies being deployed to identify causal links to disease using observational patient data or human cell models, including the challenges that come with each approach and the various computational methodologies companies are using.They also discuss the outcome of FDA’s advisory committee meetin...

    34 min
  8. Ep. 258 - Breaking the Bear: 4Q Public Markets Preview

    8 OCT.

    Ep. 258 - Breaking the Bear: 4Q Public Markets Preview

    Biopharma buysiders and bankers at long last believe the conditions are ripe for biotech growth and outperformance, BioCentury’s Stephen Hansen says on the latest BioCentury This Week podcast. Hansen and colleagues take stock of the sector’s growth potential after three long years of the bear market as they discuss BioCentury’s 4Q24 Public Markets Preview.Also on this week’s show, Washington Editor Steve Usdin discusses his Editor’s Commentary, in which he argues that FDA leaders planned refo...

    40 min
Tout afficher (274)

5
sur 5
25 notes

À propos

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Informations

  • Chaîne
    BioCentury Podcasts
  • Création
    BioCentury
  • Années d’activité
    2020 - 2024
  • Épisodes
    274
  • Classification
    Tous publics
  • Copyright
    © 2024 BioCentury Inc. All Rights Reserved.
  • Site web de l’émission
    BioCentury This Week

Plus de contenus par BioCentury Podcasts

Vous aimeriez peut‑être aussi

Pour écouter des épisodes au contenu explicite, connectez‑vous.

Recevez les dernières actualités sur cette émission

Connectez‑vous ou inscrivez‑vous pour suivre des émissions, enregistrer des épisodes et recevoir les dernières actualités.
Choisissez un pays ou une région

Afrique, Moyen‑Orient et Inde

Asie‑Pacifique

Europe

Amérique latine et Caraïbes

États‑Unis et Canada